Se connecter Inscription gratuite

Acelrx Pharmaceuticals Inc Marge bénéficiaire

Quel est le Marge bénéficiaire de Acelrx Pharmaceuticals Inc?

Le Marge bénéficiaire de Acelrx Pharmaceuticals Inc est 2,696.50%

Quelle est la définition de Marge bénéficiaire?



La marge bénéficiaire est une mesure de la rentabilité et est calculée en calculant le bénéfice net en tant que pourcentage du chiffre d'affaires.

Profit margin is calculated with the selling price (or revenue) taken as base times 100. It is the percentage of selling price that is turned into profit. Profit percentages are calculated to find the ratio of profit to cost of an investment. Profit margin is an indicator of a company's pricing strategies and how well it controls costs. Differences in competitive strategy and product mix cause the profit margin to vary among different companies. The profit margin is used mostly for internal comparisons. It is difficult to accurately compare the net profit ratio for different entities. Individual businesses' operating and financing arrangements vary so much that different entities are bound to have different levels of expenditure, so that comparison of one with another can have little meaning. A low profit margin indicates a low margin of safety: higher risk that a decline in sales will erase profits and result in a net loss, or a negative margin.

Marge bénéficiaire des entreprises dans Health Care secteur sur NASDAQ par rapport à Acelrx Pharmaceuticals Inc

Que fait Acelrx Pharmaceuticals Inc?

acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v

Entreprises avec marge bénéficiaire similaire à Acelrx Pharmaceuticals Inc